/oss/taxonomy/term/7085/all en /oss/article/medical-health-and-nutrition/what-next-evolution-glp-1-based-therapies-diabetes-and-obesity <p>The first glucagon-like peptide-1 (GLP-1)-based therapeutic was approved by Health Canada in 2011 for the treatment of hyperglycemia in patients with Type 2 diabetes. Little was it suspected at that time that this class of drugs would go on to become a global success not only for Type 2 diabetes but, now, also for people living with overweight/obesity. Since that time, numerous variants of GLP-1 have been developed, with at least 7 different forms in trials or available today.</p> Fri, 15 Dec 2023 20:17:14 +0000 Patricia Brubaker, Ph.D., F.R.S.C. 9763 at /oss /oss/article/medical-health-and-nutrition/who-needs-guts <p>Imagine not being able to eat a meal with family or friends. That is the case for people who have a condition known as short bowel syndrome (SBS). When large segments of the intestines are missing, often due to surgery for disease or trauma, patients can be left with insufficient bowel to absorb dietary nutrients and fluids, also called intestinal failure. These processes normally take place in the small intestine (i.e., absorption of ingested carbohydrate, fat, protein and vitamins) and large intestine (i.e., water absorption).</p> Fri, 08 Sep 2023 10:00:00 +0000 Patricia Brubaker, Ph.D., F.R.S.C. 9623 at /oss